Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. is convening its first extraordinary general meeting of shareholders in 2025 on September 10, 2025, utilizing both on-site and online voting methods [1][2]. Meeting Basic Information - The meeting type is the first extraordinary general meeting of shareholders in 2025 [1]. - The meeting is convened by the Board of Directors following the sixth meeting of the tenth Board [1]. - Voting will be conducted through a combination of on-site and online methods [1]. - The on-site meeting will take place at the company's conference room in Taizhou, Zhejiang Province, starting at 14:00 on September 10, 2025 [1]. - Online voting will be available on the Shanghai Stock Exchange's shareholder meeting voting system from 9:15 to 15:00 on the same day [1]. Voting Procedures - Shareholders involved in margin trading, transfer, and other related accounts must follow the relevant regulations for voting [2]. - The meeting will review proposals that have been disclosed in advance through various media [3]. - There are no separate votes for minority investors or related shareholders [4]. Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited after the close of trading on the registration date are eligible to attend [7]. - Registration for attendance can be done in person or through written authorization for representatives [9]. - Registration will occur on September 8, 2025, at the company's securities department [11]. Additional Information - The meeting will last half a day, and attendees are responsible for their own travel and accommodation [13]. - The company will provide a reminder service for shareholders to ensure participation in the voting process [13]. - Contact information for the company is provided for further inquiries [14].

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. is set to hold its first extraordinary general meeting of shareholders in 2025 on September 10, 2025, utilizing both on-site and online voting methods [2][3]. Meeting Details - The meeting will take place on September 10, 2025, at 14:00 in the company's conference room located at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province [3][9]. - The voting will be conducted through the Shanghai Stock Exchange's online voting system, with specific time slots for trading system voting and internet voting [3][4]. Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system, either through a designated trading terminal or the internet voting platform [6][7]. - Shareholders holding multiple accounts can aggregate their voting rights across all accounts for the same category of shares [7][8]. Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the close of trading on the registration date are eligible to attend the meeting [9]. - Registration for attendance can be done in person or via mail/fax, with specific registration times set for September 8, 2025 [12][13]. Additional Information - The company aims to enhance participation from small and medium investors by providing reminder services through SMS notifications about the meeting and voting [14]. - The meeting will last for half a day, and attendees are responsible for their own travel and accommodation [14].

Core Points - The Zhejiang Haizheng Pharmaceutical Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 on September 10, 2025, to discuss key proposals [1][2] - The agenda includes the revision of the remuneration management system for directors and senior management, the cancellation of the supervisory board, and amendments to the company's articles of association [3][4] Meeting Agenda - The meeting will start with the announcement of the qualification review results of attending representatives [1] - Proposals to be reviewed include the revision of the remuneration management system for directors and senior management, which has already been approved by the board [1][3] - Shareholders and their authorized representatives will have the opportunity to speak and ask questions [1] - Voting will be conducted on the proposals, followed by the counting of valid votes [1][2] - The results of the voting will be announced, and the resolutions of the shareholders' meeting will be read [1][2] Proposal Details - Proposal 1 involves the cancellation of the supervisory board and amendments to the company's articles of association, with the supervisory board's responsibilities being transferred to the audit committee of the board [3][4] - Proposal 2 focuses on the formulation, revision, and abolition of certain corporate governance systems to enhance the company's operational standards and governance structure [4]

证券日报网讯9月3日晚间，海正药业（600267）发布公告称，公司将于2025年9月10日召开2025年第一 次临时股东大会。本次股东大会将审议《关于取消监事会并修订 <公司章程> 的议案》《关于制定、修 订、废止部分公司治理制度的议案》等多项议案。 ...

Market Performance - The Artemisinin concept index rose by 0.17%, ranking third among concept sectors, with three stocks increasing in value, including Baihua Medicine which hit the daily limit, and Fosun Pharma and China Resources Sanjiu which rose by 0.39% and 0.05% respectively [1] - The top gainers in the Artemisinin sector were Baihua Medicine, Fosun Pharma, and China Resources Sanjiu, while the biggest losers included Delong Huineng, New Harmony, and Zhejiang Medicine, which fell by 3.33%, 1.18%, and 1.17% respectively [1] Capital Flow - The Artemisinin concept sector experienced a net outflow of 58 million yuan in main capital, with Baihua Medicine receiving the highest net inflow of 109 million yuan, followed by China Resources Sanjiu and Zhejiang Medicine with net inflows of 14.16 million yuan and 5.79 million yuan respectively [2] - The net inflow ratios for Baihua Medicine, China Resources Sanjiu, and Zhejiang Medicine were 29.47%, 5.98%, and 2.65% respectively, indicating strong interest in these stocks [3] Stock Performance Details - Baihua Medicine had a daily increase of 10.03% with a turnover rate of 9.48% and a main capital flow of 108.91 million yuan, leading the sector [3] - Other notable stocks included China Resources Sanjiu with a slight increase of 0.05% and a turnover rate of 1.18%, and Zhejiang Medicine which decreased by 1.17% with a turnover rate of 1.48% [3][4]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 10, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1][2] - The on-site meeting will take place at the company's conference room located at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province [1][6] Voting Procedures - Online voting will be conducted through the Shanghai Stock Exchange's shareholder meeting online voting system, available from 9:15 AM to 3:00 PM on the day of the meeting [2][4] - Shareholders can vote via the trading system during specific trading hours [2] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [4] Agenda Items - The meeting will review several proposals, including amendments to the company's management systems and governance rules [3][7] - The proposal to revise the remuneration management system for directors and senior management has already been approved by the board [3] Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited as of the close of trading on September 4, 2025, are eligible to attend [5] - Registration for attendance must be completed by September 8, 2025, with specific documentation required [5][6] Additional Services - The company will provide a reminder service for shareholders to ensure participation in the meeting through SMS notifications [6]

浙江海正药业股份有限公司 2025 年第一次临时股东大会会议资料 浙江海正药业股份有限公司 2025 年第一次临时股东大会会议资料 二○二五年九月十日 浙江海正药业股份有限公司 2025 年第一次临时股东大会会议资料 会议议程 时间：2025 年 9 月 10 日（周三）下午 14：00，会期半天 地点：浙江海正药业股份有限公司（以下简称"公司"）会议室（台州市椒江区外沙 路 46 号） 主要议程： 上述议案已经公司第十届董事会第六次会议审议通过，具体内容详见 2025 年 8 月 26 日的《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 （www.sse.com.cn）。 三、股东及其授权代表发言及答疑 四、对上述各议案进行投票表决 五、统计有效表决票 2 1、总监票组织监票小组 2、股东及股东代表投票 一、宣布大会开始并宣布到会代表资格审查结果 二、审议下列议案 | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于取消监事会并修订《公司章程》的议案 | | 2.00 | 关于制定、修订、废止部分公司治理制度的议案 | | 2.01 | 关于修订 ...

证券代码：600267 证券简称：海正药业 公告编号：2025-52 号 浙江海正药业股份有限公司 浙江海正药业股份有限公司（以下简称"公司"）于2025年8月26日在《中 国证券报》《上海证券报》《证券时报》和上海证券交易所网站（www.sse.com.cn） 上刊登了《浙江海正药业股份有限公司关于召开2025年第一次临时股东大会的通 知》（公告编号：临2025-49号）。本次股东大会采用现场和网络投票相结合的 方式召开，现发布本次临时股东大会提示性公告。 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会，经第十届董事会第六次会议召开。 关于召开2025年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 10 日 14 点 00 分 召开地点：浙江海正药业股份有限公 ...

Core Insights - The pet industry is witnessing a clear capital landscape as the mid-year financial reporting season concludes, characterized by leading companies maintaining their positions, accelerated expansion in niche markets, and deepening global layouts [1] - Most companies have achieved varying degrees of revenue growth, while a few face performance pressures due to single business models, reflecting rapid domestic market expansion, the rise of private brands, and product structure optimization [1] Revenue Growth - Yuanfei Pet leads with a 45.52% year-on-year revenue growth, totaling 791 million yuan, driven by a 64.63% increase in pet snacks and a 55.39% rise in pet food [2] - Guobao Pet reported a total revenue of 3.22 billion yuan, up 32.72%, with a net profit of 378 million yuan, a 22.55% increase, primarily from domestic private brand contributions [2] - Zhongchong Co. achieved a revenue of 2.432 billion yuan, a 24.32% increase, with a net profit of 203 million yuan, reflecting strong cost control [2] - Tianjin Langnuo's revenue reached 138 million yuan, up 21.16%, with cat food sales driving growth [3] - Jianhe Group's pet nutrition and care products generated 1.08 billion yuan, an 8.6% increase, with high-end supplements growing by 14.3% [3] - Peti Co. is one of the few companies experiencing revenue decline, with a total revenue of 727 million yuan, down 13.94% [3] Strategic Investments - Companies are increasingly investing in global capacity layout, supply chain extension, private brand development, and digital transformation, which are expected to provide long-term competitive advantages [4] - Zhongchong Co. has established a factory in Mexico, becoming the first Chinese pet food company to do so, aiming to create a responsive global supply chain [4] - Yiyi Co. has also made progress in overseas capacity layout with a factory in Cambodia, producing nearly 300 million pet pads annually [4] - Ruipuhua is focusing on building a supply chain network with 13 regional companies covering 13,000 clients, including 8,400 pet hospitals and 3,500 pet stores [5] Brand Development - The establishment of factories is accelerating the development of private brands, with companies like Yuanfei Pet and Jianhe Group increasing investments in brand building to enhance product value and consumer loyalty [6] - Yuanfei Pet is expanding its domestic market presence through its own brands and distribution of international brands, creating a comprehensive product matrix [5][6] Market Outlook - The pet industry is optimistic about the second half of the year, with companies planning to focus on product innovation, market expansion, and supply chain optimization [7] - Ruipuhua plans to launch new products such as cat interferon and probiotics, while Haizheng Dongbao will expand into innovative and non-pharmaceutical areas [7] - Companies like Yuanfei Pet and Zhongchong Co. are aiming to balance domestic and international market structures through strategic expansions [7][8]

Core Viewpoint - The companion animal business of leading animal health companies in China, such as Hai Zheng Dong Bao, Rui Pu Sheng Wu, and Jin He Sheng Wu, has shown significant growth, driven by product innovation and channel expansion, indicating a shift towards the companion animal market amid the rising "pet economy" [1][2]. Group 1: Company Performance - Rui Pu Sheng Wu's pet business achieved a revenue of 415 million yuan, a year-on-year increase of 17.94%, with the pet supply chain revenue reaching 376 million yuan, up 18.49% [1]. - Hai Zheng Dong Bao's pet business grew over 60%, with expectations that pet business will account for over 50% of its total revenue by 2025 [2]. - Jin He Sheng Wu is actively advancing its pet health business, currently offering 15 pet products, including 8 health products and 1 rabies vaccine [2]. Group 2: Product Innovation - Rui Pu Sheng Wu focuses on technological research and development, holding 115 new veterinary drug registration certificates, including 17 for pet products [3]. - Hai Zheng Dong Bao emphasizes the optimization and upgrading of pet medicines, with products like Xi Bei An being the only compliant compound for cat deworming [3]. - Jin He Sheng Wu has made significant progress in pet vaccine research, recently obtaining a patent for a dual-subunit vaccine for feline infectious respiratory disease and feline panleukopenia [3]. Group 3: Sales Expansion - Rui Pu Sheng Wu has established a nationwide pet medical supply chain service network, reaching 8,400 pet hospitals and 3,500 pet stores, with ongoing expansion into new regional markets [3]. - Hai Zheng Dong Bao is enhancing its online self-operated e-commerce capabilities, achieving over 100 million yuan in sales during the first half of the year, with a significant increase in orders during the "618" shopping festival [3]. - Jin He Sheng Wu is leveraging AI technology to create a digital channel through its pet app "Ai Chong Yi," which integrates service and sales, enhancing user engagement and sales opportunities [4].